SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease

SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease

SGLT2 inhibitors, a class of type 2 diabetes medication, reduce cardiovascular events in patients beyond expectation from blood sugar control. Here the authors report a randomized controlled trial showing that SGLT2 inhibitors reduce inflammasome activation in peripheral macrophages, which may contr...

Full description

Bibliographic Details
Main Authors: So Ra Kim, Sang-Guk Lee, Soo Hyun Kim, Jin Hee Kim, Eunhye Choi, Wonhee Cho, John Hoon Rim, Inhwa Hwang, Chan Joo Lee, Minyoung Lee, Chang-Myung Oh, Justin Y. Jeon, Heon Yung Gee, Jeong-Ho Kim, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Myung-Shik Lee, Je-Wook Yu, Jin Won Cho, Jung-Sun Kim, Yong-ho Lee
Format: Article
Language:English
Published: Nature Portfolio 2020-05-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-020-15983-6

Internet

https://doi.org/10.1038/s41467-020-15983-6

Similar Items